Literature DB >> 2899913

Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide). A case report.

A S Alberts1, G Falkson.   

Abstract

A patient with life-threatening hypoglycaemia caused by metastatic malignant insulinoma is described. Treatment with octreotide (SMS 201-995, Sandostatin; Sandoz) resulted in immediate sustained improvement of the hypoglycaemia despite persistent high levels of insulin. The possible mechanisms of action, other indications and contraindications of octreotide are discussed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2899913

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

Review 1.  Malignant insulinoma: spectrum of unusual clinical features.

Authors:  Boaz Hirshberg; Craig Cochran; Monica C Skarulis; Steven K Libutti; H Richard Alexander; Bradford J Wood; Richard Chang; David E Kleiner; Phillip Gorden
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

Review 2.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 3.  Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.

Authors:  Philippe E R Lheureux; Soheil Zahir; Andrea Penaloza; Mireille Gris
Journal:  Crit Care       Date:  2005-09-07       Impact factor: 9.097

4.  Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature.

Authors:  Anoopa A Koshy; Ilyssa O Gordon; Thuong G Van Ha; Edwin L Kaplan; Louis H Philipson
Journal:  J Investig Med High Impact Case Rep       Date:  2013-01-01

Review 5.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.